Polygenic score informed by genome-wide association studies of multiple ancestries and related traits improves risk prediction for coronary artery disease

Competing Interest Statement

S.A. has served as a scientific advisor to Third Rock Ventures. A.C.F. is a co-founder of Goodpath and reports a grant from Abbott Vascular. P.T.E. receives sponsored research support from Bayer AG and IBM Research; he has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. P.N. reports investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston Scientific, and Novartis, personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Novartis, Roche / Genentech, is a co-founder of TenSixteen Bio, is a scientific advisory board member of Esperion Therapeutics, geneXwell, and TenSixteen Bio, and spousal employment at Vertex Pharmaceuticals, all unrelated to the present work. A.V.K. is an employee of Verve Therapeutics; has served as a scientific advisor to Amgen, Novartis, Silence Therapeutics, Korro Bio, Veritas International, Color Health, Third Rock Ventures, Illumina, Ambry, and Foresite Labs; holds equity in Verve Therapeutics, Color Health, and Foresite Labs; and is listed as a co-inventor on patent applications related to assessment and mitigation of risk associated with perturbations in body fat distribution.

Funding Statement

This work was supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (to A.P.P. and K.G.A.); the Sarnoff Cardiovascular Research Foundation Fellowship (to S.A.); grants 1K08HL153937 (to K.G.A.),1K08HL161448 (to A.C.F.), R01HL1427 (to P.N.), R01HL148565 (to P.N.), R01HL148050 (to P.N.), 1RO1HL092577 (to P.T.E.), 1R01HL157635 (to P.T.E.), and 1R01HL157635 (to P.T.E.) from the National Heart, Lung, and Blood Institute; grant 862032 (to K.A.) and grants 18SFRN34110082 (to P.T.E.), 17IFUNP3384001 (to .G.A.) from the American Heart Association; grant MAESTRIA 965286 from the European Union (to P.T.E.); grants 1K08HG010155 and 1U01HG011719 from the National Human Genome Research Institute (to A.P.P., P.N., and A.V.K.); a Hassenfeld Scholar Award from Massachusetts General Hospital (to P.N. and A.V.K.); a Merkin Institute Fellowship from the Broad Institute of MIT and Harvard (to A.V.K.). This research has been conducted using the UK Biobank Resource, and we thank the volunteers participating. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by Veterans Administration awards I01-01BX003362, I01-BX004821 (P.S.T), I01-BX003340 (P.W.F.W) and VA HSR RES 13-457 (VA Informatics and Computing Infrastructure). The content of this manuscript does not represent the views of the Department of Veterans Affairs or the United States Government. Genes & Health is/has recently been core-funded by Wellcome (WT102627, WT210561), the Medical Research Council (UK) (M009017, MR/X009777/1, MR/X009920/1), Higher Education Funding Council for England Catalyst, Barts Charity (845/1796), Health Data Research UK (for London substantive site), and research delivery support from the NHS National Institute for Health Research Clinical Research Network (North Thames). Genes & Health is/has recently been funded by Alnylam Pharmaceuticals, Genomics PLC; and a Life Sciences Industry Consortium of Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. We thank Social Action for Health, Centre of The Cell, members of our Community Advisory Group, and staff who have recruited and collected data from volunteers. We thank the NIHR National Biosample Centre (UK Biocentre), the Social Genetic & Developmental Psychiatry Centre (King's College London), Wellcome Sanger Institute, and Broad Institute for sample processing, genotyping, sequencing and variant annotation. We thank: Barts Health NHS Trust, NHS Clinical Commissioning Groups (City and Hackney, Waltham Forest, Tower Hamlets, Newham, Redbridge, Havering, Barking and Dagenham), East London NHS Foundation Trust, Bradford Teaching Hospitals NHS Foundation Trust, Public Health England (especially David Wyllie), Discovery Data Service/Endeavour Health Charitable Trust (especially David Stables), NHS Digital - for GDPR-compliant data sharing backed by individual written informed consent. Most of all we thank all of the volunteers participating in Genes & Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research and secondary data use was approved by the Mass General Brigham institutional review board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes